GEN Exclusives

More »

GEN News Highlights

More »
Jul 21, 2011

BioSante Licenses Melanoma Vaccine to Hussman Foundation

  • BioSante Pharmaceuticals signed an exclusive, worldwide license of its melanoma vaccine to the John P. Hussman Foundation. Under the agreement, the foundation has committed up to approximately $11 million in clinical development funding that will allow for the vaccine’s first clinical trial.

    BioSante received $100,000 on signing the license and is eligible for up to $39 million in milestone payments, plus royalties on sales. Also, BioSante will receive between 15% and 33% of any sublicense payments received by the Hussman foundation, depending on the timing of any sublicense by the foundation to a corporate sublicensee.

    “The foundation intends to move rapidly into human clinical trials,” states Stephen M. Simes, BioSante’s president & CEO. “Assuming a successful outcome of the first Phase I clinical trial, the foundation will fund a Phase II clinical trial with the objective of obtaining further clinical evidence, and engaging a corporate sponsor for Phase III clinical trials.”

    BioSante expects to begin the first Phase I trial within the next several months. The clinical trial protocol is being finalized, and a quantity of vaccine has been produced for the trial.

    The company was granted orphan drug designation in the treatment of stage IIb to IV melanoma by the FDA in January.The designation is BioSante's fourth for its pipeline of cancer vaccines, which includes vaccines for pancreatic cancer, acute myeloid leukemia, and chronic myeloid leukemia. The firm is also developing a vaccine for breast cancer.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »